Vernalis Research
Parent HitGen | | |
| Website | vernalis.com | |
|---|---|---|
Vernalis Research develops and applies
anti-infectives and inflammation
.
History
Following the sale of Vernalis plc[4] on 10 October 2018, Vernalis Research became a subsidiary of Ligand Holdings UK Ltd, wholly owned by Ligand Pharmaceuticals, Inc. On 2 December 2020, HitGen (Chengdu, China), acquired the entire issued share capital of Vernalis (R&D) Limited.[5]
Their scientists, based at
A2A.[16]
As well as an internal portfolio of drug discovery projects, Vernalis Research has a number of research collaborations on targets with large pharmaceutical companies and academic partners. Recently disclosed collaborations include those with
Queen's Award for Enterprise, for outstanding achievement in International Trade, endorsing both the talent and capabilities of its research group, and recognition of the growing overseas earnings it has achieved.[19]
Vernalis Research has delivered a number of drug candidates into clinical development, some of which remained as part of the
Chk1 oncology research programme.[6]
References
- ISBN 9780128130698.
- S2CID 19634793.
- PMID 21371604.
- ^ "Recommended Cash Offer for Vernalis plc by Ligand Holdings UK (Ltd) (a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated)". London Stock Exchange. Retrieved 14 December 2018.
- ^ "HitGen to Acquire Vernalis, a Leader in Structure-Based Drug Discovery". Businesswire. Retrieved 3 December 2020.
- ^ PMID 26437226.
- PMID 18020435.
- ^ .
- PMID 18413753.
- PMID 19610616.
- PMID 20371713.
- ^ PMID 29732004.
- ^ S2CID 4472590.
- S2CID 198194567.
- PMID 26987975.
- PMID 19072055.
- PMID 29023112.
- PMID 28314412.
- ^ "Vernalis Research «". Queensawardmagazine.com. Retrieved 14 December 2018.
- ^ Clinical trial number NCT01748695 for "A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury" at ClinicalTrials.gov
